Shakespeare Wealth Management LLC Invests $223,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)

Shakespeare Wealth Management LLC purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 7,398 shares of the biopharmaceutical company's stock, valued at approximately $223,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Captrust Financial Advisors grew its position in TG Therapeutics by 21.1% during the 3rd quarter. Captrust Financial Advisors now owns 30,327 shares of the biopharmaceutical company's stock worth $709,000 after acquiring an additional 5,279 shares during the last quarter. HighTower Advisors LLC increased its stake in shares of TG Therapeutics by 19.6% in the third quarter. HighTower Advisors LLC now owns 12,526 shares of the biopharmaceutical company's stock valued at $294,000 after buying an additional 2,053 shares during the period. State Street Corp raised its holdings in TG Therapeutics by 35.8% in the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company's stock valued at $212,712,000 after buying an additional 2,398,015 shares during the last quarter. Wellington Management Group LLP boosted its position in TG Therapeutics by 12.7% during the 3rd quarter. Wellington Management Group LLP now owns 73,320 shares of the biopharmaceutical company's stock worth $1,715,000 after buying an additional 8,249 shares during the period. Finally, Castleark Management LLC acquired a new stake in TG Therapeutics during the 3rd quarter worth approximately $3,948,000. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Trading Up 2.0 %

Shares of TGTX traded up $0.73 during trading hours on Friday, hitting $36.71. 2,052,937 shares of the stock were exchanged, compared to its average volume of 3,110,585. The firm has a market capitalization of $5.77 billion, a P/E ratio of -367.06 and a beta of 2.14. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics, Inc. has a fifty-two week low of $12.93 and a fifty-two week high of $43.32. The business has a 50-day moving average of $35.76 and a 200-day moving average of $31.39.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million. On average, research analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, TG Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $40.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.